|
|
Blood, Vol. 113, Issue 5, 1062-1070, January 29, 2009
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
Blood Goldenberg et al.
113: 1062
Supplemental materials for: Goldenberg et al
Files in this Data Supplement:
- Document 1. Supplemental methods and results (PDF, 63.5 KB)
- Table S1. Individual mouse serum PK of veltuzumab administered as a single intraperitoneal injection (PDF, 51.5 KB)
- Table S2. Individual mouse serum PK of veltuzumab administered as a single subcutaneous injection (PDF, 51.5 KB)
- Figure S1. Alignment of A20, c2B8, and hA20 chains (JPG, 95.1 KB)
-
(A) Alignment of A20, c2B8, and hA20 VH chains. Dots indicate homology to A20; green text, framework residues; boxed region with red text, CDR. (B) Alignment of A20, c2B8, and hA20 Vk chains. Dots indicate homology to A20; green text, framework residues; boxed region with red text, CDR.
- Figure S2. Binding characteristics of veltuzumab and rituximab were determined by binding the 125I-labeled mAbs to Raji cells (JPG, 69.4 KB)
-
Direct cell surface saturation binding and Scatchard plot analysis (insert). Closed triangle: veltuzumab; open circle: rituximab. Bmax and Kd were determined by non-linear regression analysis using a one-site binding model with Prism software. These results are representative of one of three repeated experiments.
- Figure S3. Effects of veltuzumab and rituximab on proliferation of non-Hodgkin’s lymphoma cell lines (JPG, 47.8 KB)
-
Anti-proliferative effects were assessed by MTT cytotoxicity assays. Cells were cultured with the mAbs with or without a second antibody for crosslinking. White bars, no second antibody; gray bars with GAH second antibody; error bars, SD.
- Figure S4. PK of veltuzumab in normal mice (JPG, 26.8 KB)
-
Veltuzumab (150 µg) was administered to naïve Swiss-Webster mice either via the i.p. or s.c. route. Animals were bled over a 14-day period and serum was assayed for veltuzumab concentrations as described in the Methods section. (N=6).
|
|
